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Abstract 45 
 46 
In 2014, the European Medicines Agency (EMA) released for comment a draft reflection 47 
paper on the use of patient-reported outcome (PRO) measures in oncology studies. A twelve-48 
member International Society for Quality of Life Research (ISOQOL) taskforce was 49 
convened to coordinate the ISOQOL response. Twenty-one ISOQOL members provided 50 
detailed comments and suggestions on the paper; 81% from academia, and 19% from 51 
industry. Taskforce members consolidated and further refined these comments and shared the 52 
recommendations with the wider ISOQOL membership. A final response was submitted to 53 
the EMA in November 2014. 54 
 55 
The impending publication of the EMA reflection paper presents a valuable opportunity for 56 
ISOQOL to comment on the current direction of EMA PRO guidance and strategy. The 57 
paper, although focused on cancer, could serve as a model for using PROs in other conditions, 58 
as it provides a useful update surrounding some of the design issues common to all trial 59 
research including PRO endpoints. However, we believe there are a number of additional 60 
areas in need of greater consideration. The purpose of this commentary is therefore to 61 
highlight the strengths of this timely and potentially useful document, but also to outline areas 62 
that may warrant further discussion.  63 
 64 
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  69 
The European Medicines Agency (EMA) has released for comment a reflection paper on the 70 
use of patient-reported outcome (PRO) measures in oncology studies [1]. This updates their 71 
2005 publication [2]. The purpose of the proposed reflection appears two-IROGWRµVSXUDQ72 
open discussion on the value of PRO data in the development of medicinal products¶LQ73 
oncology; and to present recommendations surrounding optimal PRO trial design - both with 74 
a focus on the regulatory perspective. 75 
 76 
The EMA invited public comments on the draft reflection paper in June 2014. An 77 
International Society for Quality of Life Research (ISOQOL) taskforce (authors listed on this 78 
commentary) was convened to coordinate the ISOQOL response. Twenty-one ISOQOL 79 
members provided detailed comments and suggestions on the EMA Reflection Paper; 81% 80 
from academia, and 19% from industry. Taskforce members consolidated and further refined 81 
these comments and shared the recommendations with the ISOQOL members through its 82 
member listserv. A final response was submitted to the EMA in November 2014 [placeholder 83 
for ISOQOL EMA response web-page reference]. 84 
 85 
The impending publication of the EMA reflection paper presents a valuable opportunity to 86 
comment on the current direction of EMA PRO guidance and strategy. The purpose of this 87 
commentary is therefore to highlight the strengths of this timely and potentially useful 88 
document, but also to outline areas that may warrant further discussion.  89 
 90 
Signs of encouragement 91 
 92 
:HQRWHWKH(0$¶VXVHRIWHUPLQRORJ\KDVVKLIWHGIURPhealth-related quality of life (HRQL) 93 
to the umbrella term patient-reported outcomes (PROs). This change reflects the broader 94 
context for the capture of patient experiences and perspectives as, in addition to HRQL, they 95 
may also include such domains as symptom burden, functional impact, treatment 96 
concordance, treatment satisfaction and global health status. 97 
 98 
Within the document, the EMA extols the virtues of rigorous PRO trial design. In particular 99 
they highlight the importance of: a strong rationale, supporting both PRO collection itself and 100 
the timing of assessment; comprehensive training of trial staff and patients involved in PRO 101 
measurement; implementation of methods to maximize compliance; and the formulation of a 102 
detailed, PRO-specific, statistical analysis plan addressing special issues such as multiplicity 103 
and missing data. This approach is welcome: both experience and empirical research suggests 104 
a failure to incorporate these design features during trial planning may result in PRO data that 105 
are uninformative or inappropriate for evaluating the harms and benefits of the intervention 106 
under study.[3; 4] The EMA recommendations also align with those presented in other 107 
contemporary PRO guidance documents, including those produced by the Center for Medical 108 
Technology Policy [5] and the U.S. Food and Drug Administration (FDA) [6]. The apparent 109 
harmonization of EMA and FDA guidance is encouraging, and it is hoped that further 110 
alignment in the coming years may allow sponsors to adopt a unified PRO claim strategy 111 
across the two agencies. Harmonization on PRO guidance would also benefit from the 112 
involvement of perspectives from researchers in industry and academic institutions and from 113 
patient groups. As a good model, the U.S. National Cancer Institute convened a Clinical 114 
Trials Planning Meeting in 2011 that included researchers, regulators, and patient 115 
representatives to recommend a core set of symptoms to measure in adult cancer clinical trials 116 
[7]. The core set will promote consistent assessment of patient-centered and clinically-117 
relevant symptoms to capture in oncology research. 118 
 119 
Areas requiring greater focus  120 
 121 
Although the EMA paper rightly highlights the importance of PRO trial design, a greater 122 
consideration of the issues surrounding PRO reporting is required. Poor reporting of PRO 123 
data ± which limits their use to inform clinical care, guidelines and health policy ± has been 124 
identified as a particular problem in trials research [8; 9]. Therefore, we believe the EMA 125 
should also outline the importance of transparent and high quality reporting of PRO endpoints 126 
in the final version of their reflection, and formally lend its support to the use of the 2013 127 
CONSORT-PRO extension [9] to address this issue. ,6242/WKURXJKLWVµBest Practices for 128 
PROs in Randomized Clinical Trials¶WDVNIRUFH [10], is currently undertaking work to tackle 129 
both poor PRO trial design and reporting: including the development of a protocol checklist 130 
which will facilitate optimal design of PRO endpoints in trials, and of user-centered tools for 131 
implementing the CONSORT PRO extension. Greater collaboration between the EMA and 132 
ISOQOL is encouraged to facilitate future improvements in PRO trial design, implementation 133 
and reporting. 134 
 135 
In their draft reflection, the EMA question the value of longitudinal PRO data; stating they 136 
KDYHµ«UDUely been informative from a licensing SHUVSHFWLYH«a main reason being the 137 
DEVHQFHRIGHPRQVWUDWHGGLIIHUHQFHEHWZHHQWKHVWXG\DUPV¶ [1]. We understand that lack of 138 
difference in PROs between study arms might be seen as a challenge. However, we also 139 
emphasize that if the PRO data: (i) are of high quality; (ii) arise from a robustly designed and 140 
adequately powered PRO substudy, with a clear and comprehensive trial protocol; and (iii) 141 
the results are appropriately reported in later publications; the information derived ± even if it 142 
LVD³QR352GLIIHUHQFH´UHVXOW± may effectively inform clinical decision-making when 143 
considered with other clinical endpoints evaluating overall treatment impact. There are 144 
pivotal trials, for example in brain cancer patients, where only marginal differences in PROs 145 
between treatment arms have been found; yet these have contributed to a better understanding 146 
RIWKHµYDOXH¶RIWKHQHZWUHDWPHQWXQGHULQYHVWLJDWLRQ [11]. We urge the EMA to recognize 147 
that the lack of difference in PROs between treatment arms should not be seen, per se, as a 148 
factor limiting the use of PRO data in informing licensing decisions. Further, a finding of no 149 
HRQL difference does not imply a lack of difference between treatment arms in relevant and 150 
more specific PRO domains, such as symptoms. 151 
 152 
We also encourage the EMA to provide transparent data surrounding historical PRO labeling 153 
claims, alongside more detailed information regarding the final decision. Ideally it would be 154 
useful to know how many products had PROs in the labels, but also how many had requested 155 
PROs, and the reasons why PRO labels were not approved. This information would be of 156 
major interest to readers, as it would shed light on the current value of PRO data in 157 
interpreting treatment effectiveness. Presentation of case studies, outlining successful PRO 158 
labeling claims, would also be of great benefit to the research community and would help 159 
guide future improvements in PRO trial design. 160 
 161 
Whilst we recognize that this is a reflection paper, it may also be a useful medium to consider 162 
contemporary challenges in oncology PRO trial design. For example, while it is quite 163 
straightforward to link PRO assessment to specific clinical events in case of a conventional 164 
chemotherapy-based trial (e.g. administering questionnaires in conjunction with the clinical 165 
visit), newer therapies pose challenges that investigators need to consider when developing a 166 
protocol. For instance, issues around µWLPLQJ¶and adherence become more challenging in 167 
trials investigating modern targeted therapies such as tyrosine-kinase inhibitors (TKIs); as 168 
these treatments are usually taken by patients on a daily basis (and in most cases for a 169 
prolonged period of months or years). We take for granted that the patient has received the 170 
recommended dose of chemotherapy or radiotherapy, as the patient has to attend their hospital 171 
and receive treatment in the clinic. However, anti-cancer-targeted therapies are typically 172 
administered orally, not requiring a hospital visit. It has been shown that adherence with 173 
targeted agents (e.g. leukemia patients) is not optimal and might undermine maximum benefit 174 
of therapy [12]. Patient-reported measures may be used to capture both the extent of 175 
medication adherence and reasons for non-adherence, which may include such issues as 176 
treatment toxicity, costs, or forgetting the medication. Thus, EMA consideration of the 177 
challenges and opportunities associated with PRO evaluation in targeted therapies would be 178 
helpful. 179 
 180 
Finally, the last decade has seen increasing interest in the contribution of patients as active 181 
partners in health research. Growing evidence reflects the beneficial impact of patient 182 
engagement in enhancing the quality, relevance and validity of such research [13; 14]; and in 183 
particular within patient-centered outcomes research (PCOR) [15; 16]. For example, recent 184 
PCOR has sought to identify outcomes that really matter to patients [17] and improve the 185 
relevance and validity of PRO measures [18], with the aim of enhancing the acceptability of 186 
PRO-based assessment and improving compliance. The EMA reflection raises issues 187 
DVVRFLDWHGZLWKµUHVSRQGHQWEXUGHQ¶DQG352VHOHFWLRQEXWIDLOVWRRXWOLQHWKDWWKHVHFDQEH188 
usefully explored and addressed with appropriate, active patient engagement. Of note, for 189 
many patients, completion of a relevant and appropriate measure may indeed be empowering; 190 
respondent burden may be more readily associated with completion of irrelevant and 191 
inappropriate measures [3]. We suggest the EMA consider the value of involving patient 192 
stakeholders in the co-production of PRO trial components, with particular emphasis on: 193 
informing the selection of appropriate patient-centered endpoints; identifying relevant, 194 
acceptable and relatively un-burdensome measures of those endpoints; enhancing compliance 195 
with PRO assessment; and aiding interpretation of PRO findings and dissemination of the 196 
results. 197 
 198 
Summary 199 
 200 
The EMA draft reflection paper, although focused on cancer, could serve as a model for using 201 
PROs in other conditions: the paper provides a useful update surrounding some of the design 202 
issues common to all trial research including PRO endpoints. However, there are a number of 203 
additional areas in need of greater consideration, including: the importance of the CONSORT 204 
PRO Extension in driving up standards of reporting; the value of µnegative¶ PRO findings; the 205 
need for comprehensive information surrounding historical labeling decisions; and the role of 206 
patients in the PRO trial design and implementation. Importantly, there is also an opportunity 207 
for the EMA to outline how they might look to tackle future opportunities and barriers in the 208 
field of PROs research and how to make best use of PRO data. 209 
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